Results of Galmed’s Phase 2b ARREST Trial of Aramchol Published in Nature Medicine
October 11, 2021 12:00 pm Leave your thoughts– Data add to the growing body of clinical and scientific evidence demonstrating the therapeutic potential of Aramchol, a stearoyl CoA desaturase (SCD 1) down regulator, for the treatment of NASH and Fibrosis
Categorised in: Uncategorized
This post was written by admin